Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 24.48 USD 0.74% Market Closed
Market Cap: 139.2B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PFE stock under the Base Case scenario is 32.54 USD. Compared to the current market price of 24.48 USD, Pfizer Inc is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PFE Relative Value
Base Case
32.54 USD
Undervaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.2
P/S
P/S
Price to Sales
2.2
vs History
82
vs Industry
47
Median 3Y
2.4
Median 5Y
2.7
Industry
2.5
Forward
2.2
More Details
17.7
P/E
P/E
Price to Earnings
17.7
vs History
26
vs Industry
26
Median 3Y
8.8
Median 5Y
11.9
Industry
21.5
Forward
8
More Details
9.9
P/OCF
P/OCF
Price to OCF
9.9
vs History
55
vs Industry
31
Median 3Y
11.8
Median 5Y
11.1
Industry
16.6
More Details
334
P/FCFE
P/FCFE
Price to FCFE
334
vs History
1
vs Industry
23
Median 3Y
9.4
Median 5Y
8.5
Industry
24.9
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
95
vs Industry
47
Median 3Y
1.8
Median 5Y
2.4
Industry
2.1
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
65
vs Industry
36
Median 3Y
2.8
Median 5Y
3.4
Industry
2.7
Forward
2.9
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
77
vs Industry
46
Median 3Y
4
Median 5Y
4.9
Industry
5.2
More Details
7.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.6
vs History
66
vs Industry
36
Median 3Y
7.3
Median 5Y
8.3
Industry
12.8
Forward
7.1
More Details
10.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.6
vs History
60
vs Industry
33
Median 3Y
10.3
Median 5Y
11.4
Industry
16.3
Forward
8.2
More Details
12.9
EV/OCF
EV/OCF
Enterprise Value to OCF
12.9
vs History
55
vs Industry
25
Median 3Y
14
Median 5Y
13.2
Industry
14.9
More Details
16.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.1
vs History
50
vs Industry
20
Median 3Y
19.1
Median 5Y
16.1
Industry
17.9
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
93
vs Industry
58
Median 3Y
1.1
Median 5Y
1.3
Industry
1.9
More Details

Multiples Across Competitors

PFE Competitors Multiples
Pfizer Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pfizer Inc
NYSE:PFE
139.2B USD 2.2 17.7 7.6 10.6
US
Eli Lilly and Co
NYSE:LLY
766.3B USD 15.6 69 37 40.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.3
CH
Roche Holding AG
SIX:ROG
215.6B CHF 3.6 26 9.8 11.4
CH
Novartis AG
SIX:NOVN
190.5B CHF 4.4 18.1 10.7 14.3
UK
AstraZeneca PLC
LSE:AZN
169.5B GBP 4.2 29.6 131.3 198
US
Merck & Co Inc
NYSE:MRK
202.1B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
108.4B EUR 1.2 8.6 4.7 5.6
P/E Multiple
Earnings Growth PEG
US
Pfizer Inc
NYSE:PFE
Average P/E: 24.4
17.7
31%
0.6
US
Eli Lilly and Co
NYSE:LLY
69
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
26
32%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
8.6
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pfizer Inc
NYSE:PFE
Average EV/EBITDA: 395
7.6
2%
3.8
US
Eli Lilly and Co
NYSE:LLY
37
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.8
5%
2
CH
Novartis AG
SIX:NOVN
10.7
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.3
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
4.7
7%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pfizer Inc
NYSE:PFE
Average EV/EBIT: 1 698.4
10.6
10%
1.1
US
Eli Lilly and Co
NYSE:LLY
40.4
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.3
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
198
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.6
14%
0.4

See Also

Summary
PFE intrinsic value, competitors valuation, and company profile.
DCF Valuation
PFE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PFE stock valuation using valuation multiples.
Wall Street Estimates
PFE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PFE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 261,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.